Telix Pharmaceuticals Limited · ASX:TLX
Telix Pharmaceuticals — Corporate Update (April 2023)
14 slides from Telix Pharmaceuticals's corporate update, Apr 27, 2023
Slide 1: Presentation: Telix's AI Development Program and Dedicaid Acquisition
Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria, 3051 Australia ASX RELEASE Presentation: Telix’s AI Development Program and Dedicaid Acquisition Melbourne (Australia) – 27 April 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) refers to th
Slide 2: Legal notices and forward-looking statements
statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking s
Slide 3: Dedicaid Acquisition
Dedicaid Acquisition Adding a new dimension of clinical decision support to our Artificial Intelligence (AI) platform Telix Pharmaceuticals (ASX:TLX) 27 April 2023
Slide 4: Disclaimer
Disclaimer The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied,
Slide 5: Contents
Contents 04 AI in healthcare and medical imaging 05 Telix’s AI strategy 06 Telix’s AI platform 10 Dedicaid acquisition rationale 11 Telix AI™: next steps
Slide 6: The role of AI in healthcare and medical imaging
The role of AI in healthcare and medical imaging Despite major advances, challenges remain in routine clinical diagnosis The increased use of medical imaging is AI can help to overcome these challenges creating multiple workforce challenges: and optimise image-based diagnosis: • Helps clinicians bet
Slide 7: Telix's AI strategy
Telix’s AI strategy Earlier, more accurate diagnosis, and personalised disease predictions Diagnosis, prediction Aligned to our Commercial and productivity theranostic pipeline edge A platform that addresses key • Applicable to multiple disease • Favourably differentiated clinical and workforce need
Slide 8: Supercharging our AI platform: Telix AI
Supercharging our AI platform: Telix AI™ The Dedicaid acquisition adds a new dimension of clinical support Reader Support (existing)1 Clinical Decision Support2 Increases efficiency and reproducibility Predicts disease outcomes including potential of imaging assessments: risk, severity and response
Slide 9: Reader Support: Enhancing molecular imaging
Reader Support: Enhancing molecular imaging Developed by Telix in partnership with Invicro Reader Support Smith, John Overview Increases efficiency and reproducibility Pilot developed and being prepared of imaging assessments: for FDA and CE Mark filing: • Automates lesion segmentation • Model train
Slide 10: Reader Support: Case study
Reader Support: Case study AI may increase the efficiency and reproducibility of clinicians’ imaging assessments Case 1 Case 2 Case 3 Original AI removes AI bone Original AI removes normal AI lymph node Original AI removes normal AI prostate scan normal uptake segmentation scan uptake (blue) segment
Slide 11: Clinical decision support designed for nuclear medicine
Clinical decision support designed for nuclear medicine Dedicaid acquisition enhances predictive capabilities of Telix’s AI platform Two major components of the platform • Clinical Decision Support System Dedicated Frontend Dedicated Backend (CDSS): Rapidly generates indication- (Browser) (CDSS + Au
Slide 12: Dedicaid provides a powerful AI development platform
Dedicaid provides a powerful AI development platform Greatly enhances Telix’s ability to rapidly generate new applications from imaging data Favourably differentiated from • Current AI solutions in nuclear medicine can support interpretation and competitor solutions reading of images – but lack pred
Slide 13: Telix AI: Next steps
Telix AI™: Next steps Go-to-market strategy Regulatory filing Illuccix commercial alignment Indication expansion • Near-term availability to key • Build CDSS application • Build CDSS applications and opinion leaders as a research supported by Illuccix seek regulatory approval for tool, establish val
Slide 14: Contact
Contact Kyahn Williamson SVP Investor Relations and Corporate Communication kyahn.williamson@telixpharma.com 12
Telix Pharmaceuticals — Corporate Update (April 2023) on 6ix